- Home
- Applications
- cancer diagnosis
Refine by
Cancer Diagnosis Product Applications For The Served Medical Health Care Industry
6 applications found
Because of the higher accumulation in tumoral areas PLGA nanoparticles are also useful for cancer diagnosis and imaging which has a key role in clinical oncology to early detection and accurate prognosis. ...
ByNanovex Biotechnologies based in Llanera, SPAIN
In 2022, nearly 30,000 Alabama men and women will be diagnosed with cancer, and more than 10,000 will die from the disease. The Information is Power campaign facilitated through the HudsonAlpha Institute for Biotechnology has offered free or reduced-cost hereditary cancer risk testing to our community of Northern Alabama in collaboration with Kailos Genetics since 2015. Information is Power uses the Expedio™ Hereditary Cancer Screening Service to review 33 genes for genetic mutations that may increase your ...
ByKailos Genetics, LLC. based in Huntsville, ALABAMA (USA)
Cancer is one of the leading causes of deaths in India and a major public health concern. It is estimated that there are around 1 million new cancer cases every year and as many as 5 lakh deaths occur annually. Around 71% of all cancer deaths in India occur in people 30 to 69 years of age, when adults are very productive. The burden of cancer is expected to further increase due to increase in life expectancy, heavy use of tobacco and other risk factors such as radiation, viruses, ...
ByinDNA Research Labs based in , INDIA
Our team at AIROS Medical is comprised of healthcare industry veterans who have developed relationships with physicians and clinicians in various ...
ByAIROS Medical Inc based in Audubon, PENNSYLVANIA (USA)
A liquid biopsy from Biocept gives you a new tool for profiling breast cancer—with a simple blood ...
ByBiocept based in San Diego, CALIFORNIA (USA)
Standard treatment for advanced colorectal cancer generally involves surgical resection and chemotherapy. However, the recent emergence of targeted therapies, particularly those that inhibit EGFR, has provided treatment options that extend survival for a subset of patients. Unfortunately, this benefit does not extend to patients whose tumors contain mutations in EGFR signaling components KRAS and BRAF, which together represent 50% of all colorectal cancers. This makes characterizing these molecular markers an ...
ByBiocept based in San Diego, CALIFORNIA (USA)